GenSight Biologics (Euronext: SIGHT) has seen its share price nearly triple since late October as expectations rise on its lead product candidate, and the company kept the good data coming with a presentation on Wednesday.
The French biotech reported sustained quality of life improvements at week 72 of the Phase III REVERSE trial of its gene therapy GS010 for leber hereditary optic neuropathy (LHON).
Composite score and relevant sub-scores in a National Eye Institute visual function questionnaire showed sustained improvements at week 48 and week 72.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze